Drug intelligence / Profile preview

TVG-PRRSV vaccine

Development stage: Preclinical
Lead developer: TVG
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies, Vaccines & Immunotherapeutics

Overview

TVG-PRRSV vaccine is a herpesvirus-based viral-vector vaccine developed by The Vaccine Group (TVG) for the prevention of Porcine Reproductive and Respiratory Syndrome (PRRS) in pigs. The vaccine utilizes a herpesvirus vector to deliver and express antigens from the Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). This approach is designed to induce robust protective immunity, specifically T-cell responses, which have been shown in preclinical studies to prevent lung disease associated with PRRSV infection in swine. The vaccine is currently in preclinical development.

Other names: Porcine Reproductive and Respiratory Syndrome vaccinePRRSV vaccine

Targets

PRRSV M (PRRSV membrane protein)

Beyond the preview

Go deeper on TVG-PRRSV vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TVG-PRRSV vaccine.

Explore the full profile